Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, Torres KE. Kochat V, et al. Among authors: tang m. Acta Neuropathol. 2021 Sep;142(3):565-590. doi: 10.1007/s00401-021-02341-z. Epub 2021 Jul 20. Acta Neuropathol. 2021. PMID: 34283254
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Terranova CJ, Tang M, Maitituoheti M, Raman AT, Ghosh AK, Schulz J, Amin SB, Orouji E, Tomczak K, Sarkar S, Oba J, Creasy C, Wu CJ, Khan S, Lazcano R, Wani K, Singh A, Barrodia P, Zhao D, Chen K, Haydu LE, Wang WL, Lazar AJ, Woodman SE, Bernatchez C, Rai K. Terranova CJ, et al. Among authors: tang m. Cell Rep. 2021 Jul 20;36(3):109410. doi: 10.1016/j.celrep.2021.109410. Cell Rep. 2021. PMID: 34289358 Free PMC article.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Maitituoheti M, et al. Among authors: tang m. Cell Rep. 2020 Oct 20;33(3):108293. doi: 10.1016/j.celrep.2020.108293. Cell Rep. 2020. PMID: 33086062 Free PMC article.
Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer.
Orouji E, Raman AT, Singh AK, Sorokin A, Arslan E, Ghosh AK, Schulz J, Terranova C, Jiang S, Tang M, Maitituoheti M, Callahan SC, Barrodia P, Tomczak K, Jiang Y, Jiang Z, Davis JS, Ghosh S, Lee HM, Reyes-Uribe L, Chang K, Liu Y, Chen H, Azhdarinia A, Morris J, Vilar E, Carmon KS, Kopetz SE, Rai K. Orouji E, et al. Among authors: tang m. Gut. 2022 May;71(5):938-949. doi: 10.1136/gutjnl-2020-322835. Epub 2021 May 31. Gut. 2022. PMID: 34059508 Free PMC article.
High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma.
Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, Skinner HD, Pickering CR, Myers JN, Rai K. Callahan SC, et al. Among authors: tang m. Front Cell Dev Biol. 2022 Jul 19;10:936168. doi: 10.3389/fcell.2022.936168. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35927986 Free PMC article.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, Lee MG. Alam H, et al. Among authors: tang m. Cancer Cell. 2020 Apr 13;37(4):599-617.e7. doi: 10.1016/j.ccell.2020.03.005. Epub 2020 Apr 2. Cancer Cell. 2020. PMID: 32243837 Free PMC article.
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics.
Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. Tang M, et al. Nat Commun. 2021 Dec 6;12(1):7081. doi: 10.1038/s41467-021-27341-1. Nat Commun. 2021. PMID: 34873156 Free PMC article.
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.
Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Chen R, et al. Among authors: tang m. J Exp Clin Cancer Res. 2022 May 11;41(1):172. doi: 10.1186/s13046-022-02361-x. J Exp Clin Cancer Res. 2022. PMID: 35546239 Free PMC article.
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Jin Y, et al. Among authors: tang m. Oncogene. 2020 Feb;39(9):1846-1859. doi: 10.1038/s41388-019-1104-z. Epub 2019 Nov 21. Oncogene. 2020. PMID: 31754213
9,258 results